Table 3 Baseline characteristics of ACPA-negative RA patients per MBDA category
MBDA category | p value | |||
|---|---|---|---|---|
< 30 (n = 17) | 30–44 (n = 29) | > 44 (n = 95) | ||
Age in years, mean (SD) | 48 (16) | 60 (13) | 62 (14) | < 0.001 |
Female, n (%) | 13 (76) | 22 (76) | 58 (61) | 0.21 |
Symptom duration in weeks, median (IQR) | 26 (8–41) | 12 (4–25) | 12 (5–22) | 0.13 |
(Sub)acute symptom onset, n (%) | 3 (20) | 7 (26) | 46 (52) | 0.01 |
66-SJC, median (IQR) | 3 (2–7) | 6 (3–13) | 9 (3–13) | 0.08 |
68-TJC, median (IQR) | 12 (9–19) | 11 (5–21) | 9 (4–17) | 0.23 |
RF positivity, n (%) | 7 (41) | 9 (31) | 33 (35) | 0.78 |
ESR (mm/h), median (IQR) | 9 (4–14) | 14 (6–33) | 33 (19–48) | < 0.001 |
CRP (µg/mL), median (IQR) | 3 (3–3) | 3 (3–4) | 22 (11–44) | < 0.001 |